Bio Techne Ownership
| TECH Stock | USD 66.78 0.92 1.40% |
Shares in Circulation | First Issued 1989-09-30 | Previous Quarter 156.4 M | Current Value 157 M | Avarage Shares Outstanding 152.6 M | Quarterly Volatility 12.6 M |
Bio Stock Ownership Analysis
About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.83. Bio Techne Corp last dividend was issued on the 13th of February 2026. The entity had 4:1 split on the 30th of November 2022. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people. To find out more about Bio Techne Corp contact Charles Kummeth at 612 379 8854 or learn more at https://www.bio-techne.com.Besides selling stocks to institutional investors, Bio Techne also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bio Techne's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bio Techne's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bio Techne Quarterly Liabilities And Stockholders Equity |
|
Bio Techne Insider Trades History
Less than 1% of Bio Techne Corp are currently held by insiders. Unlike Bio Techne's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bio Techne's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bio Techne's insider trades
Bio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Techne is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Techne Corp backward and forwards among themselves. Bio Techne's institutional investor refers to the entity that pools money to purchase Bio Techne's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Mairs & Power Inc | 2025-06-30 | 2.7 M | Champlain Investment Partners, Llc | 2025-06-30 | 2.7 M | Mackenzie Investments | 2025-06-30 | 2.6 M | Neuberger Berman Group Llc | 2025-06-30 | 2.5 M | Citadel Advisors Llc | 2025-06-30 | 2.5 M | Sumitomo Mitsui Trust Group Inc | 2025-06-30 | 2.3 M | Rgm Capital Llc | 2025-06-30 | 2.2 M | Bank Of New York Mellon Corp | 2025-06-30 | 1.9 M | Norges Bank | 2025-06-30 | 1.9 M | Vanguard Group Inc | 2025-06-30 | 18.4 M | Blackrock Inc | 2025-06-30 | 12.2 M |
Bio Techne Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Techne insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bio Techne's latest congressional trading
Congressional trading in companies like Bio Techne Corp, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Bio Techne by those in governmental positions are based on the same information available to the general public.
| 2026-02-03 | Representative April Delaney | Acquired Under $15K | Verify | ||
| 2026-01-06 | Representative April Delaney | Acquired Under $15K | Verify | ||
| 2025-11-05 | Representative April Delaney | Acquired Under $15K | Verify |
Bio Techne Outstanding Bonds
Bio Techne issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bio Techne Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bio bonds can be classified according to their maturity, which is the date when Bio Techne Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Bio Techne Corporate Filings
F4 | 5th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of February 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2025 An amended filing to the original Schedule 13G | ViewVerify |
| 19th of September 2025 Other Reports | ViewVerify |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is there potential for Life Sciences Tools & Services market expansion? Will Bio introduce new products? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.091 | Dividend Share 0.32 | Earnings Share 0.53 | Revenue Per Share | Quarterly Revenue Growth (0) |
Understanding Bio Techne Corp requires distinguishing between market price and book value, where the latter reflects Bio's accounting equity. The concept of intrinsic value - what Bio Techne's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Bio Techne's price substantially above or below its fundamental value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Bio Techne's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.